Wyeth submits NDA for desvenlafaxine extended release for depression

By Angela McDaniels

Seattle, Dec. 22 - Wyeth Pharmaceuticals said it has submitted a New Drug Application to the Food and Drug Administration for desvenlafaxine extended release (DVS-233) for the treatment of major depressive disorder.

The clinical development program supporting the NDA investigated desvenlafaxine extended release, a serotonin/norepinephrine reuptake inhibitor, in patients with a broad range of symptoms associated with depression, including both emotional and somatic symptoms.

Depression is the most common serious mental disorder worldwide, the company said, affecting 121 million people.

Wyeth Pharmaceuticals, a division of Wyeth, is based in Madison, N.J., and develops consumer and animal health care products.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.